Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10022502 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL10022466 | 0.88 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL307096 | 0.87 | ROCK2 (0.78) | ROCK2ROCK1 | |
| SCHEMBL307983 | 0.86 | ROCK2 (0.74) | ROCK2ROCK1 | |
| SCHEMBL10022448 | 0.86 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL10022456 | 0.86 | ROCK2 (0.79) | ROCK2ROCK1 | |
| SCHEMBL10022602 | 0.86 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL10022458 | 0.86 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL10022454 | 0.86 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL307011 | 0.85 | ROCK2 (0.73) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012006203-A1 | N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.